Drugs / Inhaled Nitric Oxide
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03135860 | Oct 2016 → Aug 2017 | chronic obstructive pulmonary disease, pulmonary hypertension | Bellerophon | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02851472 | Feb 2019 → Feb 2021 | anemia | New York Medical College | Unknown | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT03873298 | Mar 2019 → Mar 2020 | chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis | Rabin Medical Center | Unknown | Missed primary |
| Phase 2 | NCT01172691 | Jul 2010 → Jan 2014 | — | Baylor Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00041574 | Apr 2002 → Dec 2005 | lung disorder, pulmonary hypertension, sickle cell disease | Mallinckrodt | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00515281 | May 2008 → Jun 2023 | bronchopulmonary dysplasia, intracerebral hemorrhage, periventricular leukomalacia | University of Chicago | Terminated | No outcome recorded Stop: Enrollment |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT02652429 | Mar 2016 → Apr 2023 | pulmonary arterial hypertension | Bellerophon Pulse Technologies | Unknown | No outcome recorded |
| Phase 3 | NCT00931632 | Nov 2009 → May 2013 | bronchopulmonary dysplasia | Mallinckrodt | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01891500 | May 2016 → Sep 2019 | persistent fetal circulation syndrome, pulmonary hypertension, neonatal | University of Florida | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05213676 Comparator | Nov 2025 → Oct 2030 expected | congenital diaphragmatic hernia | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inhaled nitric oxide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03873298 ↗ |
| Known as | iNO | “Inhaled nitric oxide (iNO) is an FDA approved drug for the treatment of hypoxic respiratory failure (HRF) in term and late-preterm babies greater than 34 weeks gestation.” NCT01891500 ↗5“Inhaled nitric oxide (iNO) selectively acts on the pulmonary vasculature of ventilated lung tissue” PMID 38724947 ↗ May 2024 “inhaled nitric oxide (iNO; a vasodilator)” NCT02851472 ↗ “Inhaled Nitric Oxide (iNO) use” NCT05213676 ↗ “Inhaled Nitric Oxide (iNO)” NCT02652429 ↗ “Inhaled Nitric Oxide (iNO)” NCT01172691 ↗ |
| Route | Inhaled | “Inhaled Nitric Oxide will be delivered through the INOpulse®” NCT00041574 ↗ |